黄秀芳,中医内科学博士,中级职称,助理研究员,2018年毕业于中山大学,2021年毕业于广州中医药大学,2021年进入广州中医药大学岭南医学研究中心专职从事科研工作,师从于广东省名中医刘小虹教授,研究方向为中医药防治肺系疾病。项目申报人主要研究方向是综合运用生物信息学,网络药理学及分子生物学实验,挖掘肺系疾病发病相关机制,探索中医药治疗肺系疾病的具体作用途径。目前主持国家级课题1项,省级课题1项,市级课题1项,厅级课题1项,院内人才项目1项,在研经费60w余,参与国家级课题2项,省级课题2项,广东省重点领域研发计划项目1项;已发表SCI论文15篇(最高IF=8.78,包含数篇中科院1区TOP文章3篇,包括高引文章3篇,引用次数分别为30,23和18),中文核心论著8篇,参与院内制剂研发2项,协助指导硕士研究生8名,博士研究生7名,科学研究能力扎实,前期科研基础夯实。
✿ 主持或参与课题 ✿
1、国家自然科学基金青年项目,82204985,基于EIF4E驱动HIF-1α/ROS信号轴活化介导的线粒体功能障碍探讨射麻止喘液抑制气道上皮细胞EMT改善哮喘气道重塑的研究,2023/01-2025/12,30万元,在研,主持。
2、广东省自然面上项目,内质网应激IRE1/XBP1信号通路调控AGR2诱导NA气道上皮MUC5AC表达机制和射麻止喘液的干预作用研究,2023-01至2025-12,10万元,在研,主持。
3、广州市科技化项目,基于NLRP3/IL-1β信号轴诱发线粒体功能障碍探讨祛风化痰法抑制哮喘气道上皮EMT的机制,2023-01至2024-12,5万元,在研,主持。
4、广东省教育厅项目青年创新人才项目,2022KQNCX013,基于JAK2/STAT3信号轴介导的Th17/Treg细胞亚群偏移探讨射麻止喘液调控重症哮喘“免疫-炎症”网络紊乱的机制研究,2023/01-2024/12,2.5万元,在研,主持。
5、广州中医药大学第一附属医院中青年骨干培育项目,广州中医药大学第一附属医院青优人才项目,2024/01-2026/12,10万,主持;
6、广东省自然科学基金,2021A1515010146,基于mTOR/NLRP3炎性小体通路探讨射麻止喘液治疗中性粒细胞型哮喘的分子机制研究, 2021-01至2023-10,10万元,在研,重要参与;
7、广东省自然科学基金面上项目,2020A151501058,基于ROS/NLRP3炎性小体探讨祛风化痰法调控中性粒细胞型哮喘炎症机制的研究,2019-10至2022-09,10万元,已结题,重要参与。
8、广州市科学技术局项目,基于网络药理学探讨射麻止喘液干预支气管哮喘气道炎症信号通路的研究,2019-04至2022-03,10万,已结题,重要参与;
9、广东省科技厅项目,祛风化痰法对激素抵抗哮喘小鼠气道炎症的干预及对Nrf2信号通道的氧化应激调控研究, 2018-05至2021-04,10万,已结题,重要参与。
✿ 发表论文 ✿
[1]通讯作者. Bronchial Epithelial Transcriptomics and experimental validation reveal asthma severity-related neutrophilc signatures and potential treatments[J]. Communications Biology,2023.(IF=5.9,中科院1区TOP期刊)
[2]通讯作者. Insights into potential mechanisms of asthma patients with COVID-19: A study based on the gene expression profiling of bronchoalveolar lavage fluid[J]. Computers in Biology and Medicine, 2022.(IF=7.7中科院1区TOP期刊)
[3]通讯作者.Integrated Multi-Omics and Network Pharmacology Approach Reveal the Protection of Yiqi Huoxue Formula Against Idiopathic Pulmonary Fibrosis through Interfering Core Transcription Factors. PHYTOMEDICINE, 2022.(IF=7.9,中科院1区TOP期刊)
[4]通讯作者. A practical strategy for exploring pharmacological mechanism of luteolin against COVID-19/asthma co-morbidity: findings of system pharmacology and bioinformatic analysis[J]. Frontiers in immunology,2022.(IF=8.786)
[5]通讯作者. ITGAM-macrophage modulation as a potential strategy for treating neutrophilic Asthma: insights from bioinformatics analysis and in vivo experiments[J]Apoptosis,2023.(IF=7.2)
[6]通讯作者. Network-based analysis between SARS-CoV-2 receptor ACE2 and commonhost factors in COVID-19 and asthma: Potential mechanistic insights [J] Biomedical Signal Processing and Control,2023.(IF=5.1)
[7]通讯作者. Modeling Kaempferol as a Potential Pharmacological Agent for COVID-19/PF Co-Occurrence Based on Bioinformatics and System Pharmacological Tools. Frontiers in Pharmacology, 2019. (IF=5.988)
[8]第一作者. Phytochemicals: Targeting Mitophagy to Treat Metabolic Disorders" [J]. Frontiers Cell and Developmental Biology, 2021.(IF=6.081)
[9]第一作者. Mitophagy in Hepatic Insulin Resistance: Therapeutic Potential and Concerns[J]. Frontiers in Pharmacology, 2019.(IF=5.988)
[10]第一作者.Glycyrrhizic acid for COVID-19: findings of targeting pivotal inflammatory pathways triggered by SARS-CoV-2[J]. Frontiers in Pharmacology, 2021.(IF=5.988)
[11]第一作者. A network pharmacology strategy to investigate the anti-inflammatory mechanism of luteolin combined with in vitro transcriptomics and proteomics[J]. Int Immunopharmacol, 2020.(IF=5.714)
[12]第一作者. A network pharmacology-based strategy for predicting anti-inflammatory targets of ephedra in treating asthma[J]. Int Immunopharmacol, 2020.(IF=5.714)
[13]第二作者. Bioinformatics Analyses of Potential miRNA-mRNA Regulatory Axis in HBV-related Hepatocellular Carcinoma[J]. Int J Med Sci,2021,18(2):335-346.(IF=3.6)
[14]第一作者. Geniposide attenuates Abeta(25-35)-induced neurotoxicity via the TLR4/NF-kappa B pathway in HT22 cells[J]. RSC ADVANCES, 2018,8(34): 18926-18937.(IF=3.1)
[15]第一作者. Exploring Molecular Mechanism of Huangqi in Treating Heart Failure Using Network Pharmacology[J]. Evid Based Complement Alternat Med, 2020, 2020:6473745.(IF=2.6)
[16]第一作者. 基于网络药理学探索射麻止喘液治疗哮喘的作用机制[J]. 中国实验方剂学杂志,2019.(中文核心)
[17]第一作者. 基于网络药理学探讨射干-麻黄治疗哮喘的机制[J]. 中成药,2020.(中文核心)
[18]第一作者. 哮喘相关基因与治疗药物的生物信息学分析[J].中国实验方剂学杂志,2020.(中文核心)